Webinar Recording — March 4, 2026

Commercial Readiness: Two Sides of the Exit Coin

Hosted by Zymewire • 45 min

What separates a functional business from a premium acquisition target? Ryan Silvester (Bourne Partners) and Elias Sayias (ILIKOS Consulting Group) break down the commercial benchmarks investors actually scrutinize — and what CROs and service providers need to fix before walking into any capital or exit conversation.

Discussion Summary

Commercial Readiness: Two Sides of the Exit Coin

March 4, 2026 Ryan Silvester — Bourne Partners
Elias Sayias — ILIKOS Consulting Group
Moderated by Ali Babar, Zymewire

01

The Stakes

Why Commercial Maturity is Non-Negotiable

The current market demands a fundamental shift in how service providers approach commercial operations. Post-COVID, providers are dealing with overconcentrated client groups, growing margin pressures, and a tighter funding environment. Revenue visibility has become everything from an investor perspective.

Investors are no longer satisfied with historical growth alone. They're digging into de-risked revenue (predictable, diversified, and defensible), TAM credibility, and the quality of commercial execution, not just activity levels.

Geographic concentration, therapeutic area concentration, and client dependency are silent valuation killers that get exposed during diligence. The question investors ask is no longer only about the results you've put up, but how you put them up.

02

The Engine

Building the Exit-Ready Commercial Engine

Exit-ready organizations don't just have busy pipelines. They have healthy pipelines built on the right foundations. Elias emphasized that sophisticated BD organizations focus on Ideal Customer Profile (ICP) and Ideal Project Profile (IPP): what is truly winnable for your organization?

Diverse, winnable project mix

No overconcentration in client, TA, or geography

Pipeline quality over volume

Weighted pipeline based on real win probability, not inflated bid counts

Critical Events framework

Knowing which sponsor lifecycle events matter and engaging at the right time

Market intelligence

Tracking funding flows, study phases, and competitive position, not just sending more emails

TAM/SAM/SOM is a moving target, not a static number. Be realistic about what you can capture and what you can deliver. Investors will pressure-test this gap, and there's often a disconnect between leadership and reps on the ground that gets exposed during diligence.

03

The Investor Lens

Securing the Premium: The Investor's Valuation Checklist

Ryan outlined the specific metrics investors evaluate during diligence. Investors buy the future, not the past.

Backlog (Contracted Revenue)

Revenue "in the bag" — balanced with early stage pipeline that signals future visibility

Weighted Pipeline

Realistic win probability on every opportunity. Not how many, but how likely

Net Revenue Retention (NRR)

Upsell and cross-sell within existing accounts signals relationship strength and service quality

Diversification Metrics

Client, TA, and geographic spread. Losing a large client raises red flags investors don't forget

TAM thresholds that shape investor perception:

Sub-$500M "Not attractive"

$500M – $1B "Interesting"

$1B+ "This checks the box"

Size alone isn't enough. Investors rebuild TAM claims through bottom-up analysis, top-down validation, and third-party verification. Most operators systematically overestimate their TAM.

04

Operations

The Operational Details That Matter

Beyond commercial strategy, Elias and Ryan discussed the operational elements that investors scrutinize but companies often underestimate: contract management, account management, compliance and SOPs, and tracking the right KPIs across operational, technology, legal, commercial, and financial dimensions.

Ryan encouraged companies to start organizing these elements 36 months before an exit. Many don't address it until the last minute, which creates unnecessary stress and risk during diligence. Elias added: "The simple little things we don't look at very often are critically important."

Key Takeaways

1

Commercial maturity now directly impacts valuation. Investors are evaluating the quality, predictability, and scalability of your commercial engine, not just top-line revenue.

2

Pipeline quality beats pipeline volume. A weighted pipeline with realistic win probability is what investors trust, not inflated bid counts.

3

TAM/SAM/SOM is a moving target. Be realistic about what you can capture and what you can deliver. Investors will pressure-test your claims.

4

Diversification de-risks revenue. Client, TA, and geographic concentration are silent killers that get exposed in diligence.

5

Organization and process matter. Contract management, SOPs, compliance, and KPI tracking separate premium exits from discounted deals.

6

Start preparing 36 months out. Don't wait until you're in investor conversations to get your house in order.

Ryan Silvester

Ryan Silvester

Investment Banker, Bourne Partners

Ryan is a specialist in global M&A and financing advisory with a dedicated focus on Pharma Services and Healthcare Technology. Representing Bourne Partners, a firm with a 25-year legacy at the forefront of healthcare finance, Ryan helps Life Sciences businesses navigate complex sell-side and buy-side transactions. His expertise lies in identifying the specific value drivers that bridge the gap between a company's current operations and its ultimate investment potential within the global healthcare ecosystem.

Bourne Partners

Elias Sayias

Elias Sayias

Founder, ILIKOS Consulting Group

Elias is a clinical research veteran with over 15 years of experience bridging the gap between clinical operations and global commercial strategy. As the founder of ILIKOS Consulting Group, he has secured over $250M in new revenue for CROs and MedTech organizations by implementing tactical, market-driven go-to-market solutions. He is dedicated to helping service providers move beyond traditional sales to build sophisticated, high-growth commercial engines.

ILIKOS Consulting Group

Ali

Ali Babar

Director of Sales, Zymewire

With a foundation in multidisciplinary scientific research spanning psychiatry and chemical engineering, Ali brings a data-driven, analytical lens to the commercial landscape. He has spent years advising commercial teams within the biotech and pharma services sectors, helping them move beyond traditional prospecting to build sophisticated, high-performance sales engines. At Zymewire, he focuses on equipping organizations with the intelligence and frameworks necessary to identify market signals and drive sustainable, scalable growth.